Synthesis+ workshop with Microsoft Teams 2020-06-08

June 18. 2020 at 2:00 p.m

Innovations in peptide chemistry 2020-05-19

Nowadays, the role of polypeptide and protein fragment type macromolecules is growing. Recognizing this, we sought to develop a state-of-the-art and low-cost method that could be a good alternative for researchers.

Advanced mass spectrometry 2020-05-19

The Institute of Chemistry of Eötvös Loránd University was enriched with an extremely valuable and rare mass spectrometer within the framework of the Level Plus Excellence Program. With the help of the instrument, which is unique in the world, our researchers can perform the structural analysis of active pharmaceutical ingredients and peptide- and protein-type molecules more accurately than ever before in the new laboratory named after the physicist István Cornides.

2. Synthesis+ conference with Microsoft Teams 2020-04-20

May 21. 2020 at 2:00 p.m

Invited speakers:

Zoltán Gáspári (PPKE) : Chapters form the structure biology of the coronavirus

Although the 2019-nCoV/SARS-CoV2/COVID-19 virus came into the spotlight of molecular biology research all of a sudden, many details of its life cycle are already known from the study of related viruses. Novel results, obtained continuously at a surprising pace, reveal the specific features of the new virus. In my lecture I provide an overview of the cellular entry, translation and replication of the virus using available protein structural data.

György M Keserű (TTK): Repositioned drugs in COVID-19 infection

Since the COVID-19 outbreak witnessed in the US and Europe, national efforts of social distancing and vaccination should be complemented by effective treatment options. The present time constraints, however, do not allow developing new therapies from scratch. Therefore, most of the treatment protocols involve repositioned drugs originally developed for different indications. This talk gives an overview on the most important treatment options and summarizes the available outcomes.

Péter Ábrányi-Balogh (TTK): ChemLearning

In the ChemLearning program ELTE, BME and TTK lecturers joined in order to help and support the education of organic chemistry at the universities. Our goal is to give a tool of nowadays technology in the lecture rooms and outside the university buildings to the hand of the students and educators. For this reason we are compiling a databank of organic chemistry problems and excercizes that can be used in Canvas and Moodle e-learning systems.


Synthesis+ workshop with Microsoft Teams 2020-04-09

April 16. 2020 at 2:00 p.m

Synthesis+ workshop_CHANGE 2020-03-05

March 19. 2020 at 2:00 p.m.

Venue: The Research Centre for Natural Sciences

Gyula Dékány: Mission: Impossible

Innovations Leading to Human Milk Oligosaccharides, Glycosphingolipids and Cancer Vaccines

The presentation will outline the scientific and innovation achievements of a small group of Hungarian scientists working abroad. The talk will also demonstrate the most important features of synthetic innovations rooted in basic research via one of the most successful innovation stories of recent times.

Synthesis+ workshop 2020-02-04

February 20. 2020 at 2:00 p.m.

Venue: The Research Centre for Natural Sciences

Lajos Szente: From early observations to product development: invention and innovation in cyclodextrin technology


1. SzintPlusz conference - invited speakers 2019-10-22

December 7. 2019 at 9:00 am

Venue: ELTE TTK 1117 Budapest, Pázmány Péter sétány 1/a, Eötvös Terem

István Greiner (Richter): Flow chemistry, benefits and shortcomings

Nowadays flow chemistry is a more and more popular topic in the synthetic chemistry journals. It is especially true if the article related to pharmaceutical industry and strict quality assured chemical processes. During the presentation unique features of this type of processes and couple of examples will be shared with the audience to give a deeper insight into the erveryday life of chemists working in this field.

Balázs Volk (Egis): Scale-up challenges in drug substance development - illustrated by Egis case studies

Development of the manufacturing processes of drug substances starting from laboratory scale through kilolab and pilot plant up to the plant-scale batch size is accompanied by numerous challenges in terms of chemistry, technology, engineering and process safety. The lecture provides some interesting recent case studies from the original and generic drug research and development activity of Egis Pharmaceuticals Plc., among others from the field of flow chemistry, cross-coupling and Diels-Alder reactions.

András Kotschy (Servier): The role of synthetic chemistry in drug discovery

The majority of the candidates addressing today's drug targets fall outside the conventional chemical space (MW>500), which leads to increased structural complexity. Synthetic methodology development is therefore a prerequisite of efficient drug discovery. The presentation dempstrates this interdependence through the story of a drug vcandidate's development.

József Répási (Soneas): Metathesis

Soneas in partnership with XiMo Ltd. is developing technologies for the production of pharmaceuticals, agrochemicals, flavour and fragrance chemicals based on metathesis since 2014. Soneas was the first company in the world producing in commercial scale the W and Mo based metathesis catalyst developed by the Nobel laurate Prof. Schrock and performs industrial scale metathesis reactions with the use of these catalysts.

István Puskás (Cyclolab): Exercises on three rings: highlights in the world of modified cyclodextrins

The three most common cyclodextrins are produced by enzymatic conversion of starch. By various synthetic procedures, these three compounds can be transformed into a common household cleaning agent in multiton scale, but some cyclodextrin derivatives were designed as critical components of analytical devices already sent by mankind to extraterrestial objects (such as Mars and comet 67P/Churyumov–Gerasimenko) searching for the traces of life. However, one may find the key use of cyclodextrin derivatives in pharmaceutical products of improved performance.

Peter Tátrai (Solvo): Drugs not only act, they also traffic: how transporter studies can inform drug development

In selecting and optimising a clinical lead, while general aspects of drug-likeness are always being kept in mind, most attention is understandably focussed on maximising the selective effect of the drug on its target. The structure of the drug, however, influences its pharmacokinetics including its interactions with drug transporter proteins just as much as its pharmacodynamics. Promising drug candidates can fail if their transporter-dependent flow at biological barriers defies expectations, or if they interfere with the transporter-mediated traffic of other important drugs. Solvo has been the industry leader in developing in vitro assays that help original drug research avoid such pitfalls by predicting drug-transporter interactions.


Szent-Györgyi Lecture: Thomas J.J. Müller 2019-10-17

Thomas J.J. Müller: Diversity oriented one-pot synthesis of functional heterocycles - rapid strategies to novel dyes and kinase inhibitors

17. October 2019, MTA TTK

Thomas Muller Jav 20191017


Szent-Györgyi Lecture: Carsten Sachse 2019-10-16

Carsten Sachse: Structural basis of p62/SQSTM1 polymers by electron Cryo-Microscopy

16. October 2019, ELTE TTK 6.511

C.Sachse 20191016